ArticleJournal of the American College of Cardiology2025
Placental Malperfusion Is Associated With Adverse Outcomes in Congenital Heart Disease and With Genetic Variants in Placental Developmental Pathways.
Article in Journal of the American College of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Allele-specific CRISPR perturbation of the imprinted Dlk1-Dio3 domain reveals regulation of BMP-NOTCH-VEGF signaling in embryonic organogenesis.Cell death and differentiation · 2026Article
- Dll4 assembles the umbilical cord and placental vasculature.JCI insight · 2026Article
- Nomogram for predicting adverse perinatal outcomes in hypertensive disorders of pregnancy complicated by fetal growth restriction.American journal of translational research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPlacental malperfusion (PMP), a vascular disorder of impaired maternal or fetal placental perfusion, is common in fetuses with congenital heart disease (CHD), yet its impact on outcomes and underlying mechanisms are unclear. Perturbation of shared developmental pathways between the fetal heart and placenta may play a role in PMP development.
objectiveThis study sought to determine whether CHD fetuses with PMP have adverse outcomes and genomic variation in vascular or placental developmental pathways.
methodsThis was a retrospective case-control study of 299 CHD fetuses with and without PMP. Maternal, genomic, placental, and outcomes data were reviewed. Placentas with PMP met pathologic criteria for maternal or fetal vascular malperfusion (Amsterdam criteria), or placental weight <10%. Rare, predicted deleterious exonic/putative splicing single nucleotide variants, small insertion/deletions, and de novo variants from trios were identified from genome sequencing data, followed by burden analysis and pathway enrichment. Mann-Whitney and Student's-t test or chi-square and Fisher exact tests were performed.
resultsPMP was present in 51% of fetuses. Nonsyndromic fetuses with PMP (n = 122) vs without PMP (n = 124) had decreased birth weight (2,986 g vs 3,330 g, P < 0.001), length (48 cm vs 48.9 cm, P < 0.001), and head circumference (33 cm vs 34 cm, P < 0.001); a longer index hospitalization (21 days vs 15 days, P = 0.04); and a trend toward increased mortality (12.3% vs 5.6%, P = 0.07). No significant differences were found in syndromic subjects. PMP was associated with increased mortality in univariable analysis (unadjusted HR: 1.5; 95% CI: 1.03-2.17; P = 0.03), with borderline significance in multivariable analysis (adjusted HR: 1.44; 95% CI: 0.995-2.09; P = 0.054). The proportion of fetuses with and without PMP with ≥1 angiogenesis pathway or de novo variant was similar and not associated with outcomes. All fetuses with PMP demonstrated distinct enrichment in de novo variants in Notch signaling (NOTCH1, NOTCH3, DLL4, SMAD6, MMP2, ID2, SOX9, CHD7) and extracellular matrix regulation and epithelial-to-mesenchymal transition (COL4A4, FN1, MMP2, VIM, TIE1, DSP, PUF60, HNRNPK, SPON1) in genes critical for trophoblast and placental vascular development.
conclusionPMP is associated with impaired fetal growth, longer hospitalization, and possibly increased mortality in CHD. CHD fetuses with PMP harbor deleterious de novo variants in several key placental and cardiac developmental pathways, which may represent important mechanisms underlying PMP in CHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.